"This expansion is keeping with our strategy to build facilities close to our customer," said Matt Jennings, president and CEO of Phillips-Medisize. "It is also consistent with our desire to leverage our highly regarded design and development capabilities to build partnerships based on assisting customers with product development and innovation.”
Phillips-Medisize recently changed its name from Phillips Plastics Corp. The company provides design and manufacturing services to the medical device and diagnostics, drug delivery and commercial markets. Annual sales are just under $500 million, with 75 percent of the total revenue coming from drug delivery, medical device and diagnostic products such as disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.